Mycological Considerations in the Topical Treatment of Superficial Fungal Infections

15. Thayikkannu AB, Kindo AJ, Veeraraghavan M. Malassezia-Can it be Ignored? Indian J Dermatol. 2015;60(4):332-9.
16. Renati S, Cukras A, Bigby M. Pityriasis versicolor. BMJ. 2015 Apr 7;350:h1394.
17. Kyriakis KP, Terzoudi S, Palamaras I, et al. Pityriasis versicolor prevalence by age and gender. Mycoses. 2006;49(6):517-8.
18. Neppelenbroek KH, Seó RS, Urban VM, et al. Identification of Candida species in the clinical laboratory: a review of conventional, commercial, and molecular techniques. Oral Dis. 2014;20(4):329-44.
19. Fallahi AA, Korbacheh P, Zaini F, et al. Candida species in cutaneous candidiasis patients in the Guilan province in Iran; identified by PCR-RFLP method Acta Med Iran. 2013;51(11):799-804.
20. Hay RJ. The management of superficial candidiasis. J Am Acad Dermatol. 1999;40(6 Pt 2):S35-42.
21. Croxtall JD, Plosker GL. Sertaconazole: a review of its use in the management of superficial mycoses in dermatology and gynaecology. Drugs. 2009;69(3):339-59.
22. Crawford F, Hollis S. Topical treatments for fungal infections of the skin and nails of the foot. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001434.
23. Rotta I, Sanchez A, Gonçalves PR, et al. Efficacy and safety of topical antifungals in the treatment of dermatomycosis: a systematic review. Br J Dermatol. 2012;166(5):927-33.
24. Rotta I, Ziegelmann PK, Otuki MF, et al. Efficacy of topical antifungals in the treatment of dermatophytosis: a mixed-treatment comparison meta-analysis involving 14 treatments. JAMA Dermatol. 2013;149(3):341-49.
25. El-Gohary M, van Zuuren EJ, Fedorowicz, Z, et al. Topical antifungal treatments for tinea cruris and tinea corporis. Cochrane Database Syst Rev. 2014 Aug 4;8:CD009992.
26. Jarratt M, Jones T, Adelglass J. Efficacy and safety of once-daily luliconazole 1% cream in patients ≥12 years of age with interdigital tinea pedis: a phase 3, randomized, double-blind,vehicle-controlled study. J Drugs Dermatol. 2014;13(7):838-46.
27. Stein Gold LF, Parish LC, Vlahovic T, et al. Efficacy and safety of naftifine HCl Gel 2% in the treatment of interdigital and moccasin type tinea pedis: pooled results from two multicenter, randomized, double-blind, vehicle-controlled trials. J Drugs Dermatol. 2013;12(8):911-18.
28. Parish LC, Parish JL, Routh HB, et al. A randomized, double-blind, vehicle-controlled efficacy and safety study of naftifine 2% cream in the treatment of tinea pedis. J Drugs Dermatol. 2011;10(11):1282-28.
29. Jones TM, Jarratt MT, Mendez-Moguel I, et al. A randomized, multicenter, double-blind, vehicle-controlled study evaluating the efficacy and safety of luliconazole cream 1% once daily for 7 days in patients aged ≥ 12 years with tinea cruris. J Drugs Dermatol. 2014;13(1):32-38
30. Pierard GE, Pierard-Franchimont C, Estrada JA. Comparative study of the activity and lingering effect of topical antifungals. Skin Pharmacol. 1993;6(3):208- 14.
31. Rosen T, Elewski BE. Failure of clotrimazole-betamethasone dipropionate cream in treatment of Microsporum canis infections. J Am Acad Dermatol. 1995;32(6):1050-1
32. Phillips RM, Rosen T. Topical antifungal agents. In: Wolverton S. (ed). Comprehensive Dermatologic Therapy. 3^rd edition. Dermatology in General Medicine. 4th ed. New York, NY: Elsevier Saunders. 2013: 460-472.
33. Villars V, Jones TC. Clinical efficacy and tolerability of terbinafine (Lamisil) – a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermatol. 1989;14(2):124-27
34. Fukushiro R, Urabe H, Kagawa S. Butenafine hydrochloride, a new antifungal agent: clinical and experimental study. In: Yamaguchi H, Kobayashi GS, Takahashi H (eds). Recent progress in antifungal therapy. New York, NY: Marcel Dekker. 1992: 147-157
35. Iwatani W1, Arika T, Yamaguchi H. Two mechanisms of butenafine action in Candida albicans. Antimicrob Agents Chemother. 1993;37(4):785-8.
36. Brito GN1, Inocêncio AC, Querido SM, et al. In vitro antifungal susceptibility of Candida spp. oral isolates from HIV-positive patients and control individuals Braz Oral Res. 2011;25(1):28-33
37. Suárez VL1, Fernández Andreu CM [In vitro susceptibility of vaginal isolates of Candida vs clotrimazole and nystatin]. Rev Cubana Med Trop. 2003;55(3):138-45. [Article in Spanish]
38. Kwok YK, Tay YK, Goh CL, Epidemiology and in vitro activity of antimycotics against candidal vaginal/skin/nail infections in Singapore. Int J Dermatol. 1998;37(2):145-9.
39. Gupta AK, Kogan N, Batra R. Pityriasis versicolor: a review of pharmacological treatment options. . Expert Opin Pharmacother. 2005;6(2):165-78
40. Alastruey-Izquierdo A, Melhem MS, Bonfietti LX, et al. Susceptibility test for fungi: Clinical and labratorial correlations in medical mycology. Rev Inst Med Trop Sao Paulo. 2015;57 Suppl 19:57-64.
41. Ghannoum MA, Arthington-Skaggs B, Chaturvedi V, et al. Interlaboratory study of quality control isolates for a broth microdilution method (modified CLSI M38-A) for testing susceptibilities of dermatophytes to antifungals. J Clin Microbiol. 2006;44(12):4353-6
42. Singh J, Zaman M, Gupta AK. Evaluation of microdilution and disk diffusion methods for antifungal susceptibility testing of dermatophytes. Med Mycol. 2007;45(7):595-602.
43. Risslegger B, Lass-Flörl C, Blum G, et al. Evaluation of a modified EUCAST fragmented-mycelium inoculum method for in vitro susceptibility testing of dermatophytes and the activity of novel antifungal agents. Antimicrob Agents Chemother. 2015;59(6):3675-82.
44. Rizi K, Murdan S, Danquah C, et al. Development of a rapid, reliable and quantitative method – “SPOTi” for testing antifungal efficacy. J Microbiol Methods. 2015;117:36-40
45. Arikan S. Current status of antifungal susceptibility testing methods. Med Mycol. 2007;45(7):569-87.
46. Sanguinetti M, Posteraro B, Lass-Flörl C. Antifungal drug resistance among Candida species: mechanisms and clinical impact. Mycoses. 2015;58 Suppl 2:2-13.
47. Koga H. Antifungal susceptibility testing method for dermatophytes -determination of MIC and MFC values. Med Mycol J. 2014;55(2):J57-63
48. Palacin C, Sacristan A, Ortiz JA. In vitro activity of sertaconazole. Arzneimittelforschung. 1992;42 (5A):699-705.
49. Nolting S. Investigation of the antibacterial effect of the antifungal agent naftifine: left versus right clinical comparative study between naftifine and gentamicin in pyoderma. Mykosen. 1987;30(suppl 1):70-77.
50. Nolting S, Brautigam M. Clinical relevance of the antibacterial activity of terbinafine: a contralateral comparison between 1% terbinafine cream and 0.1% gentamicin sulphate cream in pyoderma. Br J Dermatol. 1992;126(Suppl 39):56–60.
51. Riviera L, Bellotti M. Laboratory evaluation of ciclopirox olamine: In vitro and in vivo studies on its antimicrobial activity. Chemotherapia. 1983;2(2):97–102.
52. Kokjohn K, Bradley M, Griffiths B, et al. Evaluation of in vitro activity of ciclopirox olamine, butenafine HCL and econazole nitrate against dermatophytes, yeasts and bacteria. Int J Dermatol. 2003;42(Suppl 1):11–7.
53. Hanel H, Smith-Kurtz E, Pastowsky S. Therapy of seborrheic eczema with an antifungal agent with an antiphlogistic effect. Mycoses. 1991;34(Suppl 1):91–3.
54. Rosen T, Schell BJ, Orengo I. Anti-inflammatory activity of antifungal preparations. Int J Dermatol. 1997;36(10):788–92.
55. Araj GF, Asmar RG, Avedissian AZ. Candida profiles and antifungal resistance evolution over a decade in Lebanon. J Infect Dev Ctries. 2015;27;9(9):997-1003.
56. Bailly S, Maubon D, Fournier P, et al. Impact of Antifungal Prescription on relative distribution and susceptibility of Candida spp - Trends over 10 Years. J Infect. 2015;Oct 27. pii: S0163-4453(15)00342-4. (e-pub)
57. Favre B, Ghannoum MA, Ryder NS. Biochemical characterization of terbinafine-resistant Trichophyton rubrum isolates. Med Mycol. 2004;42(6):525-9.
58. Osborne CS, Leitner I, Favre B, et al. Amino acid substitution in Trichophyton rubrum squalene epoxidase associated with resistance to terbinafine. Antimicrob Agents Chemother. 2005 Jul;49(7):2840-4
59. Cervelatti EP, Fachin AL, Ferreira-Nozawa MS, et al. Molecular cloning and characterization of a novel ABC transporter gene in the human pathogen Trichophyton rubrum. Med Mycol. 2006;44(2):141-7.
60. Martinez-Rossi NM, Peres NT, Rossi A. Antifungal resistance mechanisms in dermatophytes. Mycopathologia. 2008;166(5-6):369-83.
61. Yu L, Zhang W, Wang L, et al. Transcriptional profiles of the response to ketoconazole and amphotericin B in Trichophyton rubrum. Antimicrob Agents Chemother. 2007;51(1):144-53
62. Ghelardi E, Celandroni F, Gueye SA, et al. Potential of Ergosterol synthesis inhibitors to cause resistance or cross-resistance in Trichophyton rubrum. Antimicrob Agents Chemother. 2014;58(5):2825-9.
63. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5-6):353-67.

AUTHOR CORRESPONDENCE